Astria Therapeutics Stock Current Liabilities
| ATXS Stock | USD 12.55 0.04 0.32% |
Fundamental analysis of Astria Therapeutics allows traders to better anticipate movements in Astria Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Total Current Liabilities is likely to gain to about 20.1 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 3.8 M in 2025. Astria | Current Liabilities | Build AI portfolio with Astria Stock |
Astria Therapeutics Company Current Liabilities Analysis
Astria Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Astria Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Astria Therapeutics is extremely important. It helps to project a fair market value of Astria Stock properly, considering its historical fundamentals such as Current Liabilities. Since Astria Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Astria Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Astria Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Astria Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Astria Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Astria Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Astria Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Astria Therapeutics could also be used in its relative valuation, which is a method of valuing Astria Therapeutics by comparing valuation metrics of similar companies.Astria Therapeutics is currently under evaluation in current liabilities category among its peers.
Astria Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Astria Therapeutics from analyzing Astria Therapeutics' financial statements. These drivers represent accounts that assess Astria Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Astria Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 39.3M | 48.1M | 217.7M | 502.1M | 451.9M | 474.5M | |
| Enterprise Value | 15.4M | (38.0M) | 198.1M | 447.6M | 402.9M | 423.0M |
Astria Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Astria Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Astria Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Astria Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 485 M | ||||
| Shares Outstanding | 56.43 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 97.54 % | ||||
| Number Of Shares Shorted | 3.14 M | ||||
| Price To Book | 3.04 X | ||||
| Price To Sales | 1,031 X | ||||
| EBITDA | (111.56 M) | ||||
| Net Income | (94.26 M) | ||||
| Cash And Equivalents | 102.48 M | ||||
| Cash Per Share | 7.87 X | ||||
| Total Debt | 5.35 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 19.87 X | ||||
| Book Value Per Share | 3.97 X | ||||
| Cash Flow From Operations | (81.21 M) | ||||
| Short Ratio | 0.89 X | ||||
| Earnings Per Share | (2.02) X | ||||
| Target Price | 24.6 | ||||
| Number Of Employees | 78 | ||||
| Beta | 0.075 | ||||
| Market Capitalization | 708.26 M | ||||
| Total Asset | 342.36 M | ||||
| Retained Earnings | (674.79 M) | ||||
| Working Capital | 315.51 M | ||||
| Net Asset | 342.36 M |
About Astria Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Astria Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Astria Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Astria Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Astria Stock Analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.